Pharmaceutical

Catalent is laying off 350 employees at its gene therapy manufacturing division in Baltimore “due to an unexpected shift in demand from a large custom...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy in its first branded campa...

The FDA has extended its target action dates for two applications to expand the use of Eylea’s high-dose formulation. The U.S. regulator was originall...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of Decem...

A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying and shutting down struggli...

CSL is laying off up to 15% of its workforce as the company looks to cut R&D costs and spin out its vaccine subsidiary.

Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Ta...

As it brings a brand beloved in Mexico stateside, Bayer is stoking nostalgia and a sense of family and tradition to improve its reach among the Hispan...